Ftse Mib
34.603,61
0,00%
DAX
18.726,36
0,00%
S&P 500
5.321,41
0,25%
NASDAQ
16.832,62
0,22%
Bitcoin
69.839,87
-0,42%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Pyxis Oncology Inc (PYXS) Pyxis Oncology Inc (PYXS) Notizie

Pyxis Oncology Inc

PYXS
3,92
-0,27 (-6,44%)
22 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
14/5/202414:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202413:55EDGAR2Form 8-K - Current report
14/5/202413:30GLOBEPyxis Oncology Provides Corporate Update and Reports..
09/5/202413:30GLOBEPyxis Oncology to Present at the RBC Capital Markets Global..
28/3/202421:30GLOBEPyxis Oncology Reports Inducement Grants Under Nasdaq..
27/3/202412:30GLOBEPyxis Oncology Obtains $8 Million Payment for the Sale of..
21/3/202412:30GLOBEPyxis Oncology Provides Corporate Update and Reports..
13/3/202413:00GLOBEPyxis Oncology Expands Board of Directors with Appointment..
08/3/202422:03EDGAR2Form SC 13G - Statement of acquisition of beneficial..
07/3/202422:30GLOBEPyxis Oncology to Present at Leerink Global Biopharma..
05/3/202422:45GLOBEPyxis Oncology to Present New PYX-201, PYX-106 and PYX-102..
28/2/202413:02EDGAR2Form 8-K - Current report
27/2/202414:00GLOBEPyxis Oncology Announces $50 Million Private Placement
29/12/202322:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202322:30GLOBEPyxis Oncology Reports Inducement Grants Under Nasdaq..
06/12/202322:50EDGAR2Form 3 - Initial statement of beneficial ownership of..
30/11/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202313:22EDGAR2Form 8-K - Current report
28/11/202313:00GLOBEPyxis Oncology Announces Appointment of Ken Kobayashi, M.D.,..
17/11/202322:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202322:46EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202322:44EDGAR2Form 8-K - Current report
07/11/202322:30GLOBEPyxis Oncology Announces Initiatives to Prioritize Lead ADC..
27/10/202322:34EDGAR2Form 8-K/A - Current report: [Amend]
28/9/202322:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/9/202300:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/9/202300:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/9/202315:18GLOBEPyxis Oncology Announces Four Abstracts Accepted for Poster..
25/9/202323:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/9/202323:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/9/202301:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/9/202301:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202323:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202323:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202323:08EDGAR2Form 144 - Report of proposed sale of securities
31/8/202322:01GLOBEPyxis Oncology to Participate in Two Upcoming Investment..
25/8/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
23/8/202323:30EDGAR2Form S-8 POS - Securities to be offered to employees in..
23/8/202323:28EDGAR2Form POS AM - Post-Effective amendments for registration..
23/8/202323:28EDGAR2Form S-8 - Securities to be offered to employees in employee..
23/8/202314:47EDGAR2Form 8-K - Current report
23/8/202314:35GLOBEPyxis Oncology Successfully Completes Acquisition of..
11/8/202323:00EDGAR2Form 144 - Report of proposed sale of securities
11/8/202313:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202313:26EDGAR2Form 425 - Prospectuses and communications, business..
11/8/202313:25EDGAR2Form 8-K - Current report
11/8/202313:00GLOBEPyxis Oncology Reports Financial Results for Second-Quarter..
11/8/202312:35EDGAR2Form 425 - Prospectuses and communications, business..
11/8/202312:34EDGAR2Form 8-K - Current report
01/8/202323:14EDGAR2Form 144 - Report of proposed sale of securities
Apertura: 4,15 Min: 3,89 Max: 4,22
Chiusura: 4,19

La tua Cronologia

NASDAQ
PYXS
Pyxis Oncology
COIN
TYCOEUR
NASDAQ
AAZVCXX
Citigroup Global Markets...
COIN
ZILKRW
Zilliqa
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network